Applied DNA Sciences (APDN) Jumps 14% on Monkeypox Diagnostic Test
Applied DNA Sciences (APDN) jumped 14% today, based on the news that they have submitted a PCR-based Monkeypox Diagnostic Test for approval to the New York State Department of Health.
The test is named the Linea Monkeypox Virus 1.0 Assay and would be Applied DNA’s second successful Lab Developed Test in less than one year if approved by the NYSDOH.
“Our pursuit of monkeypox testing via LDT combines what we believe to be the quickest regulatory path for diagnostic approval with our proven ability to deliver short turnaround time-to-results that, as COVID-19 has taught us, can help contain virus spread,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “Upon NYSDOH approval, ADCL has the testing capacity to deploy to help keep New Yorkers safe. Moreover, as the test kit manufacturer, we maximize the control over our own supply chain to ensure both quality and availability.”
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using PCR to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.